Avelumab in First-line NSCLC (JAVELIN Lung 100)

NCT02576574 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1214

Enrollment

INDUSTRY

Sponsor class

Conditions

First Line Non-Small Cell Lung Cancer

Interventions

DRUG: Avelumab
DRUG: Pemetrexed
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Gemcitabine
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Avelumab Weekly

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]